Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 2
2004 1
2005 1
2006 2
2007 3
2009 5
2010 4
2012 2
2014 2
2015 1
2017 1
2018 1
2020 4
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Inhibitors in AKTion: ATP-competitive vs allosteric.
Lazaro G, Kostaras E, Vivanco I. Lazaro G, et al. Among authors: vivanco i. Biochem Soc Trans. 2020 Jun 30;48(3):933-943. doi: 10.1042/BST20190777. Biochem Soc Trans. 2020. PMID: 32453400 Free PMC article. Review.
[COVID, ventilation... and corticosteroids?].
Casado A, Diez RA, Ghini AS, López Ceruzzi MN, Vergara C, Vivanco IA. Casado A, et al. Among authors: vivanco ia. Medicina (B Aires). 2022;82(6):989. Medicina (B Aires). 2022. PMID: 36571548 Free article. Spanish. No abstract available.
Targeting molecular addictions in cancer.
Vivanco I. Vivanco I. Br J Cancer. 2014 Nov 25;111(11):2033-8. doi: 10.1038/bjc.2014.461. Epub 2014 Sep 30. Br J Cancer. 2014. PMID: 25268375 Free PMC article. Review.
Targeting un-MET needs in advanced non-small cell lung cancer.
Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Coleman N, et al. Among authors: vivanco i. Lung Cancer. 2022 Feb;164:56-68. doi: 10.1016/j.lungcan.2021.12.016. Epub 2021 Dec 29. Lung Cancer. 2022. PMID: 35033939 Review.
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth EC, Vlachogiannis G, Hedayat S, Harbery A, Hulkki-Wilson S, Salati M, Kouvelakis K, Fernandez-Mateos J, Cresswell GD, Fontana E, Seidlitz T, Peckitt C, Hahne JC, Lampis A, Begum R, Watkins D, Rao S, Starling N, Waddell T, Okines A, Crosby T, Mansoor W, Wadsley J, Middleton G, Fassan M, Wotherspoon A, Braconi C, Chau I, Vivanco I, Sottoriva A, Stange DE, Cunningham D, Valeri N. Smyth EC, et al. Among authors: vivanco i. Gut. 2021 Sep;70(9):1632-1641. doi: 10.1136/gutjnl-2020-322658. Epub 2020 Nov 16. Gut. 2021. PMID: 33199443 Free PMC article. Clinical Trial.
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
Gutierrez-Prat N, Zuberer HL, Mangano L, Karimaddini Z, Wolf L, Tyanova S, Wellinger LC, Marbach D, Griesser V, Pettazzoni P, Bischoff JR, Rohle D, Palladino C, Vivanco I. Gutierrez-Prat N, et al. Among authors: vivanco i. Life Sci Alliance. 2022 May 17;5(9):e202101235. doi: 10.26508/lsa.202101235. Print 2022 Sep. Life Sci Alliance. 2022. PMID: 35580987 Free PMC article.
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, Lazaro G, Calton E, Costa BM, Valenti M, De Haven Brandon A, Webber H, Tardif N, Almeida GS, Christova R, Boysen G, Richards MW, Barone G, Ford A, Bayliss R, Clarke PA, De Bono J, Gray NS, Blagg J, Robinson SP, Eccles SA, Zheleva D, Bradner JE, Molenaar J, Vivanco I, Eilers M, Workman P, Lin CY, Chesler L. Poon E, et al. Among authors: vivanco i. J Clin Invest. 2020 Nov 2;130(11):5875-5892. doi: 10.1172/JCI134132. J Clin Invest. 2020. PMID: 33016930 Free PMC article.
33 results